FONTEYNE PAUL R. 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 4, 2023
Insider Transaction Report
Form 4
FONTEYNE PAUL R.
Director
Transactions
- Award
Common Stock
2023-01-01+3,867→ 13,097 total - Award
Stock Option (Right to Buy)
2023-01-01+7,441→ 7,441 totalExercise: $51.71Exp: 2030-12-31→ Common Stock (7,441 underlying)
Footnotes (2)
- [F1]This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
- [F2]This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.